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Abstract
Aims/hypothesis Empagliflozin (EMPA), an inhibitor of the
renal sodium–glucose cotransporter (SGLT) 2, reduces the
risk of cardiovascular death in patients with type 2 diabetes.
The underlying mechanism of this effect is unknown.
Elevated cardiac cytoplasmic Na+ ([Na+]c) and Ca
2+
([Ca2+]c) concentrations and decreased mitochondrial Ca
2+
concentration ([Ca2+]m) are drivers of heart failure and cardiac








(NHE) activity were measured fluorometrically in isolated
ventricular myocytes from rabbits and rats.
Results An increase in extracellular glucose, from 5.5 mmol/l
to 11 mmol/l, resulted in increased [Na+]c and [Ca
2+]c levels.
EMPA treatment directly inhibited NHE flux, caused a reduc-
tion in [Na+]c and [Ca
2+]c and increased [Ca
2+]m. After
pretreatment with the NHE inhibitor, Cariporide, these effects
of EMPA were strongly reduced. EMPA also affected [Na+]c
and NHE flux in the absence of extracellular glucose.
Conclusions/interpretation The glucose lowering kidney-
targeted agent, EMPA, demonstrates direct cardiac effects by
lowering myocardial [Na+]c and [Ca
2+]c and enhancing
[Ca2+]m, through impairment of myocardial NHE flux, inde-
pendent of SGLT2 activity.
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Introduction
The recent Empagliflozin, Cardiovascular Outcomes, and
Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) study
has demonstrated that empagliflozin (EMPA), an inhibitor of
renal sodium-glucose cotransporter (SGLT)2, resulted in a 38%
reduction in the relative risk of cardiovascular death and a 35%
risk reduction of hospitalisation for heart failure in patients with
type 2 diabetes [1]. SGLT2 inhibitors also result in increased
urinary glucose excretion in diabetic patients. The mechanisms
behind these effects are unknown [1, 2], however, since these
findings do not suggest any beneficial effects of EMPA on the
incidence of myocardial infarction and stroke, it is unlikely that
they can be ascribed to a general reduction in risk factors for
cardiovascular disease (e.g. glycaemic status, body weight,
blood pressure). We hypothesised that EMPA has a direct car-
diac effect; since increases in myocardial intracellular Na+ and
Ca2+ concentrations are early hallmarks and drivers of cardio-
vascular death and heart failure [2–6], we investigated whether
EMPA (1) directly reduces intracellular cardiac cytoplasmic
Na+ ([Na+]c) and Ca
2+ ([Ca2+]c) concentration; (2) affect the
(upstream) cardiac Na+/H+ exchanger (NHE); and (3) changes
(downstream) mitochondrial Ca2+ concentration ([Ca2+]m).
Methods
Animal handling was in accordance with the Institutional
Animal Care and Use Committee of the VUMedical Center
and Academic Medical Center Amsterdam, and was con-
ducted according to the Guide for the Use and Care of
Laboratory Animals.
For detailed methods, see electronic supplementary material
[ESM] Methods. Cardiomyocytes were isolated from hearts
from healthy rabbits and rats. Cells were left untreated or treated
with 1 μmol/l EMPA (MedChem Express, Monmouth
Junction, NJ, USA), 5.5 mmol/l or 11 mmol/l glucose
(Sigma-Aldrich Chemie, Zwijndrecht, the Netherlands),
10 μmol/l cariporide (Aventis Pharma, Frankfurt, Germany) or
20 mmol NH4Cl (NH
+) (Sigma-Aldrich Chemie), either alone
or in combination. [Na+]c and [Ca
2+]c were fluorometrically
measured in rabbit cardiomyocytes using SBF1 and indo-1,
respectively, at 2 Hz field stimulation. NHE activity was
measured in rabbit cardiomyocytes by recording SNARF fluo-
rescence following an NH4
+ pulse. Using adenoviral transfec-
tion, a ratiometric mitochondrially targeted fluorescence reso-
nance energy transfer (FRET)-based Ca2+ indicator
(4mtD3cpv, MitoCam) was expressed in rat cardiomyocytes
and free [Ca2+]m was measured using the fluorescence ratio,
yellow fluorescent protein intensity/cyan fluorescent protein
intensity (YFP/CFP), in cultured adult rat cardiomyocytes.
Statistics Data are reported as mean ± SE. Kolmogorov–
Smirnov normality testing was applied to decide the use of
non-parametric vs parametric testing. Mann–Whitney tests
were used to evaluate the effects of glucose on Na+ and
Ca2+. ANOVAwith Dunnett’s post hoc tests was used to com-
pare group means with the control ([EMPA] 0) group.
Additionally, unpaired t tests were used to evaluate EMPA
effects on [Ca2+]c and EMPA effects on the NHE flux in the
absence of glucose, ANOVA with post hoc testing with
Bonferroni corrections were used to compare cariporide and
EMPA effects on the NHE flux in the presence of glucose and
two-way ANOVA for repeated measures followed by post hoc
contrast with Bonferroni correction at one time point were
performed to detect EMPA effects on [Ca2+]m.
Results
EMPA decreases [Ca2+]c and [Na
+]c and increases [Ca
2+]m
First, we examined the acute effects of EMPA in isolated
rabbit cardiomyocytes in the presence of 11 mmol/l glucose.
EMPA (1 μmol/l) decreased [Na+]c within 10 min (Fig. 1a).
Vehicle administration had no effect (data not shown). In ad-
dition, similar acute EMPA effects were observed for diastolic
and systolic [Ca2+]c (Fig. 1b,c).
Extended (3 h at 37°C in 3 ml HEPES buffer) EMPA incu-
bation at clinically relevant concentrations (0.25–1 μmol/l) also
reduced [Na+]c, in the presence of both 11 mmol/l (Fig. 1d) and
5.5 mmol/l (Fig. 1e) glucose. Increasing glucose concentration
from 5.5 mmol/l to 11 mmol/l significantly increased [Na+]c
(6.0±0.2 mmol/l to 7.6±0.3 mmol/l; p<0.001; Fig. 1d), dia-
stolic [Ca2+]c (68±3 nmol/l to 101±3 nmol/l; p<0.001) and
systolic [Ca2+]c (331±18 nmol/l to 435±20 nmol/l; p<0.001)
(data not shown). EMPA preincubation of cardiomyocytes at
11 mmol/l glucose also significantly lowered diastolic and sys-
tolic [Ca2+]c (Fig. 1f). Patch clamp experiments (n=4 cells)
demonstrated that 1 μmol/l EMPA had no effect on action
potential duration (data not shown). The downstream effects
of the cytosolic changes of [Na+]c and [Ca
2+]c on [Ca
2+]m were
subsequently tested. Acute EMPA (1 μmol/l) administration
significantly increased [Ca2+]m (Fig. 1g).
Collectively, these data show that EMPA reduces myo-
cardial [Na+]c and [Ca
2+]c and increases [Ca
2+]m, whereas
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increases in glucose are associated with elevated [Na+]c
and [Ca2+]c.
Empagliflozin impairs cardiac NHE activity without
SGLT involvement Because the rapid action of EMPA resem-
bled that of the NHE-inhibitor Cariporide on [Na+]c and [Ca
2+]c
[3], we investigated whether EMPA has NHE-inhibiting proper-
ties. First, we examined EMPA and Cariporide interactions on
[Na+]c. Following the reduction in [Na
+]c with EMPA, additional
application of Cariporide had only a minimal effect on [Na+]c
(Fig. 2a). Similarly, following the reduction in [Na+]c with
10 min pre-treatment with Cariporide, subsequent EMPA appli-
cation had a minimal effect on [Na+]c (Fig. 2b). Second, we
examined NHE flux, as determined by measuring pH recovery
after an acute acidic load via wash-out of NH4
+. In control
conditions, pH quickly recovered to normal values after NH4
+
wash-out. However, this recovery of pH was totally inhibited by
the specific NHE inhibitor Cariporide, reflecting reduced NHE
activity (Fig. 2c). In the presence of EMPA, the NHE flux was
also strongly reduced by approximately 80% of the reduction
observed with Cariporide (Fig. 2c). During NH4
+ application,
no significant difference in pH recovery was observed between
Cariporide and control (data not shown). Finally, we evaluated
whether SGLTs were involved in the effects of EMPA on NHE
by repeating the experiments in the absence of glucose; in
glucose-free conditions, EMPA also reduced [Na+]c (Fig. 2d)
and impaired NHE flux (Fig. 2e).
These data suggest that EMPA affects intracellular ion ho-
meostasis in the cardiomyocyte through direct interaction with














EMPA (μmol/l): 0 0.25 1.00.50





























































































































Gluc (mmol/l): 5.5 5.5 5.5 5.5
EMPA (μmol/l):
Fig. 1 EMPA effects on [Na+]c, [Ca
2+]c and [Ca
2+]m. (a–c) EMPA
(1 μmol/l) acutely lowers (a) [Na+]c, and (b) diastolic [Ca
2+]c and (c)
systolic [Ca2+]c in rabbit cardiomyocytes. (d,e) Effects of EMPA (3 h
incubation) on [Na+]c at (d) 11 mmol/l and (e) 5.5 mmol/l glucose
(Gluc), respectively. *p < 0.05 vs 0 μmol/l EMPA, ANOVA with
Dunnett’s post hoc tests. (f) Effects of EMPA (3 h pre-incubation;
[EMPA] 1) on diastolic (Dias) and systolic (Sys) [Ca2+]c at 11 mmol/l
glucose. *p< 0.05 vs 0 μmol/l EMPA ([EMPA] 0), unpaired t test. (g)
[Ca2+]m as determined by the change in fluorescence ratio, YFP/CFP,
relative to 0 min (t=0) during a 15 min incubation with 1 μmol/l EMPA
(white bars) or vehicle (black bars). *p< 0.05 vs vehicle at a similar time
point, two-way ANOVA for repeated measures followed by post hoc con-
trast with Bonferroni correction at one time point. For (a–c) n= 6–8 cells
from 3 rabbits per investigation; for (d–f), n= 20–30 cells from 3 rabbits
per investigation; for (g) n=8–9 cardiomyocytes from 2–3 rats for each
group (EMPA or vehicle)
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Discussion
The present study demonstrates for the first time that the
kidney-targeted therapeutic agent, EMPA, directly reduces
myocardial intracellular Na2+ through an interaction with the
NHE, independent of cardiac SGLT inhibition. The observed
decreased [Ca2+]c and increased [Ca
2+]m are likely to have
occurred secondary to the decrease in [Na+]c via the sarcolem-
mal and mitochondrial Na+/Ca2+ exchanger (NCX), respec-
tively [6, 7]. Dapagliflozin, another SGLT2 inhibitor with a
slightly different chemical composition, was recently shown
to reduce cell shortening after 5 min but not after 3 h of treat-
ment. It was also found to reduce systolic but not diastolic
Ca2+ in cardiomyocytes from models of type 1 diabetes (but
not in control cardiomyocytes) [8]. In comparison with
dapagliflozin, the current study indicates a stronger and longer
lasting effect of EMPA on cardiomyocytes. It is suggested that
further research is required to compare the effects of different
classes of SGLT2 inhibitors on cardiomyocytes characteristics.
EMPA: cardiac NHE and SGLT2 Our observations that the
effects of EMPA were independent of glucose presence is in
agreement with a previous observation that SGLT2 is absent
from cardiac tissue [9]. However, SGLT1 is present in the
heart [9, 10], potentially explaining the increase in [Na+]c with
increased circulating glucose. It was recently reported that
SGLT1 within the diseased human heart is mainly localised
in capillaries and not in cardiomyocytes [11]. This is in con-
trast with other observations that SGLT1 is localised in the T
tubules of isolated cardiomyocytes [10]. In the current study,
the effects of glucose on [Na+]c were detected in isolated
cardiomyocytes; therefore, it is unlikely that glucose release
from the capillaries plays a role in this effect. However, further
research is needed to study the role of SGLT1 within the intact
heart. We used EMPA concentrations in the range of clinically
measured plasma concentrations (≤1 μmol/l) [1, 12], well be-
low the IC50 of SGLT1 (8.3 μmol/l) for EMPA [13].
Therefore, EMPA does not exert its cardiac effects through
SGLT1inhibition.
EMPA raises cardiac [Ca2+]m Previous studies have demon-
strated that increasing [Na+]c results in decreased [Ca
2+]m
through increased mitochondrial efflux via the mitochondrial
NCX [7]. This is very likely to be the mechanism underlying
the EMPA-induced elevation in [Ca2+]m, observed in the pres-
ent study. Mitochondrial Ca2+ is considered to be an important
activator of ATP synthesis and of the antioxidant enzymatic
















































































Fig. 2 The effects of EMPA on the NHE in the presence and absence of
glucose. (a) Cariporide exerted little effect on [Na+]c when preceded by
EMPA inhibition. (b) Similarly, EMPAwas of little effect on [Na+]c when
preceded by Cariporide. (c) pH traces for rabbit cardiomyocytes exposed
to an acidic load (NH4
+) and during recovery for control (black solid line),
Cariporide-treated (grey line) or EMPA-treated (black dashed line) cells
in the presence of 11 mmol/l glucose. *p < 0.05 vs control for pH mea-
sured at 1000 s; †p < 0.05 vs Cariporide for pH measured at 1000 s,
ANOVA with post hoc testing with Bonferroni corrections. (d) EMPA
(1 μmol/l) acutely lowers [Na+]c even in the absence of extracellular
glucose (n= 6/3 rabbits). (e) EMPA effects on pH recovery in the absence
of extracellular glucose (n = 6/3 rabbits). Control (black solid line),
EMPA-treuted (black dashed line). *p< 0.05 vs control for pH measured
at 1000 s, unpaired t test. n= 6 cells from 3 rabbits for all except for (c),
where n= 5–6 cells from 4 rabbits
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impairment, energy deficiency and increased oxidative stress
[5, 14, 15] are hallmarks of failing hearts, restoring [Ca2+]m
(e.g. increasing [Ca2+]m that is otherwise reduced due to Na
+
loading) is predicted to be beneficial in this condition. Indeed,
in a recent study, it was demonstrated that increasing mito-
chondrial Ca2+ during heart failure development was associ-
ated with the prevention of sudden death and overt heart fail-
ure [5]. This is in contrast to conditions where [Ca2+]m is al-
ready elevated, such as during reperfusion injury phenomena,
in which further increases in [Ca2+]m can be detrimental.
EMPA and heart failure The propensities for arrhythmias,
oxidative stress and heart failure are all associated with, and at
least partly driven by, intracellular cardiomyocyte Na+ and Ca2+
loading [2, 3, 5, 6, 14]. Hyperglycaemia (as reported in this
study) and diabetes [10] also result in intracellular Na+ and
Ca2+ loading, possibly contributing to the reported interaction
between hyperglycaemia/diabetes and cardiovascular diseases.
Previous studies have demonstrated that chronic inhibition
of NHE prevents or mitigates heart failure in animal models
[16, 17]. Although clinical studies of NHE inhibition have
been performed in the setting of acute coronary syndromes
(and largely show a neutral effect) no clinical studies have
been performed using NHE inhibition in the chronic setting
of heart failure and diabetes. Therefore, these types of studies
are awaited. We surmise that the beneficial cardiovascular
effects of EMPA are, at least in part, attributed to NHE inhi-
bition. However, the current results do not allow for the gen-
eration of conclusive statements about a positive or negative
role on cardiac mitochondrial function following EMPA treat-
ment. The next area that needs to be evaluated is whether
EMPA does indeed result in beneficial functional cardiac ef-
fects, such as increased ATP production, oxygen consumption
and/or antioxidant capacity. Whether the reductions in both
cardiac [Na+]c and [Ca
2+]c with EMPA treatment, and the
downstream effect of elevated [Ca2+]m contribute to the pri-
mary mechanisms underlying the cardiovascular benefits ob-
served in the EMPA-REG OUTCOME trial needs to be ex-
amined in future research.
In conclusion, our data demonstrate that the kidney-
targeted therapeutic agent EMPA has direct cardiac effects,
decreases cardiac [Na+]c and [Ca
2+]c and increases cardiac
[Ca2+]m via inhibition of the cardiac NHE.
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